胸腺肽α1对肝细胞癌根治性手术预后的影响

  目的   探讨胸腺肽α1（Thymosin alpha 1，Tα1）对肝细胞癌（hepatocellular carcinoma，HCC）患者根治性手术预后的影响。   方法   回顾性分析本院2007年1月至2012年12月558例HCC根治性手术后患者，分为Tα1治疗组146例和空白对照组412例，经倾向性评分匹配后，比较两组术后肝功能恢复情况、无瘤生存率和总生存率。   结果   两组患者共106对匹配成功，中位随访时间为22个月，治疗组较对照组术后TBIL、ALB、ALT、PT等肝功能指标明显改善（P < 0.05）。治疗组和对照组术后1、2、3年无瘤生存率分别为79.7%、70.8%、67.3%和69.9%、61.5%、51.6%（P=0.019）；总生存率分别为87.2%、82.0%、68.4%和78.2%、64.2%、49.7%（P=0.011）。   结论   HCC根治术后应用Tα1治疗能有效改善患者术后肝功能，显著提高患者无瘤生存率和总生存率。 

Thymosin alpha 1 for patients with hepatocellular carcinoma after radical hepatectomy

  Objective   The effect of thymosin alpha 1 (T α 1) on patients with hepatocellular carcinoma (HCC) after radical hepatectomy was assessed.   Methods   A total of 558 HCC patients treated by radical hepatectomy were retrospectively collected. Patients in the treatment group (n=146) received postoperative Tα1 therapy, whereas patients in the control group (n=412) did not. Propensity scale matching was conducted to improve the balance between the two groups. Changes in liver function, recurrence-free survival rates, and overall survival rates were compared between the two groups.   Results   Postoperative liver function (i.e., TBIL, ALB, ALT, and PT) in the treatment group was significantly better than that in the control group (P < 0.05). The one-, two-, and three-year recurrence-free survival rates and overall survival rates in the treatment group were significantly higher than those in the control group (P=0.019 and P=0.011, respectively).   Conclusion   Postoperative Tα1 therapy can improve postoperative liver function, thus significantly prolonging recurrence-free survival and overall survival.